Premium Nahrungsergänzungsmittel | artgerecht

SMAD4 - Tumor Suppressor Gene & TGF-β Pathway

SMAD4 is a key tumor suppressor gene and signaling protein in the TGF-β pathway, regulating cell growth and differentiation, with a critical role in several cancers.

Regular tips about health Regular tips about health

Things worth knowing about "SMAD4"

SMAD4 is a key tumor suppressor gene and signaling protein in the TGF-β pathway, regulating cell growth and differentiation, with a critical role in several cancers.

What is SMAD4?

SMAD4 (Suppressor of Mothers against Decapentaplegic 4) is an intracellular signaling protein and a major tumor suppressor gene in humans. It plays a central role in the TGF-β signaling pathway (Transforming Growth Factor Beta), which regulates fundamental cellular processes including growth, differentiation, apoptosis (programmed cell death), and tissue formation. The SMAD4 gene is located on chromosome 18q21 and is also known as DPC4 (Deleted in Pancreatic Cancer locus 4), as it was first identified in the context of pancreatic cancer.

Function and Mechanism of Action

SMAD4 acts as a Co-SMAD, serving as a common mediator in intracellular signal transduction. The TGF-β signaling pathway proceeds as follows:

TGF-β ligands (signaling molecules) bind to specific receptors on the cell surface.
These receptors activate receptor-SMADs (R-SMADs, e.g., SMAD2 and SMAD3).
Activated R-SMADs form a complex with SMAD4.
This complex translocates to the cell nucleus, where it regulates gene expression by switching specific target genes on or off.

In this way, SMAD4 controls the activity of genes responsible for cell proliferation, differentiation, and apoptosis. When SMAD4 is functional, TGF-β acts as a growth inhibitor, protecting against uncontrolled cell division.

Clinical Relevance: SMAD4 and Cancer

Mutations or loss of the SMAD4 gene disable this protective mechanism, allowing uncontrolled cell growth and tumor development. SMAD4 alterations have been identified in several cancer types:

Pancreatic cancer: SMAD4 is inactivated in approximately 50–60% of all cases, making it one of the most frequent tumor suppressor losses in this malignancy.
Colorectal cancer: SMAD4 mutations occur in about 10–15% of cases and are associated with a poorer prognosis.
Gastric cancer and other gastrointestinal tumors.
Juvenile polyposis syndrome: Germline mutations in SMAD4 cause this rare hereditary syndrome, characterized by numerous polyps throughout the gastrointestinal tract and a significantly increased cancer risk.

SMAD4 as a Diagnostic and Prognostic Marker

Detection of SMAD4 mutations or loss (commonly via immunohistochemistry or molecular genetic analysis) carries important clinical implications:

In pancreatic cancer, SMAD4 loss is a negative prognostic factor and is associated with increased distant metastasis.
In colorectal cancer, SMAD4 status can assist in treatment decisions, particularly regarding the likelihood of response to certain chemotherapy regimens.
In juvenile polyposis syndrome, testing for SMAD4 germline mutations is an integral part of genetic counseling and family screening.

Diagnostics

Detection of SMAD4 alterations is performed using several methods:

Immunohistochemistry (IHC): Detection of protein loss in tumor tissue using specific antibodies.
Molecular genetic analysis: Next-Generation Sequencing (NGS) or PCR-based methods to identify point mutations, deletions, or other changes in the SMAD4 gene.
FISH (Fluorescence In Situ Hybridization): Detection of gene loss at the chromosomal level.

Therapeutic Relevance

SMAD4 is not only a diagnostic marker but also a target for future therapeutic strategies. Because SMAD4 loss dysregulates the TGF-β signaling pathway, researchers are developing approaches to therapeutically modulate this pathway. Currently, no approved therapies specifically target SMAD4 loss; however, SMAD4 is the subject of intensive oncological research. In precision oncology, SMAD4 status is increasingly considered during treatment planning.

References

Hahn SA, Schutte M, Hoque AT, et al. - DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350-353. PubMed PMID: 8553070.
Datto MB, Wang XF. - The Smads: transcriptional regulation and mouse models. Cytokine Growth Factor Rev. 2000;11(1-2):37-48. PubMed PMID: 10708953.
Mehrvarz Sarshekeh A, Advani S, Overman MJ, et al. - Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLOS ONE. 2017;12(3):e0173345.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.